Regulators need to rethink ‘current’ GMP requirements, says ex-FDA exec

By Flora Southey contact

- Last updated on GMT


Related tags: Current good manufacturing, Regulation, Good manufacturing practice

In the days of personalised medicine, 3D printing and nanotechnology, consultant David Chesney says regulators must “keep pace” to redefine current good manufacturing practice.

Adapting current good manufacturing practice (cGMP) to innovative technologies is a challenge for regulators, ex-US Food and Drug Administration (FDA) executive David Chesney told delegates at Dublin’s BioPharma Ambition Conference yesterday.

The general manager of DL Chesney Consulting said this issue stems from the fact many ‘current’ regulations were created in an earlier era, before numerous present-day technologies existed.

A major revision of US GMP in 1978 – finalised in 1979​ – brought ‘current’ regulations 21 CFR Parts 210 and 211​ up to date almost 40 years ago, and only relatively minor changes have been made since then.

“So we sit here, in 2018, with the US enforcing a regulation that calls itself ‘current’,” ​said Chesney.

“Regulators need to strike a balance between protecting the public from unreasonable risk and avoiding inhibition or restriction of technological advance.”

Changes in the foreseeable future?

Despite this need to advance alongside rapidly changing technologies, Chesney said he does not predict major modifications will be made to GMP legislation in the near future.

Today, the FDA relies on three strategies to keep GMP ‘current,’ he said: litigation (which leads to precedent), issuance of binding regulations, and issuance of non-binding guidelines.

Other non-binding methods used to communicate the FDA’s current thinking in the US – and in places that supply to the US market – include Warning Letters.

Related topics: Markets & Regulations, Regulations

Related news

Show more

Related products

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Related suppliers

Follow us


View more